mRNA therapies for rare diseases and cancer
Raised to date
$8.2M
of $8.2M offered across 3 Form D filings
Elixirgen Therapeutics, Inc. is a cutting-edge biotechnology firm dedicated to the development of innovative RNA therapeutics aimed at addressing a broad spectrum of medical challenges. The company is committed to providing treatment solutions for rare diseases, cancer, and aging-related conditions that currently have limited therapeutic options.
Elixirgen Therapeutics stands out for its focus on next-generation RNA therapeutics, particularly in targeting rare diseases and aging-associated conditions, backed by strategic partnerships and advanced technology platforms.
$4M round, first sold Oct 2025: $4M sold
$4M round, first sold Oct 2025: $4M sold
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Nov 13, 2025 | Security to be acquired | $4M/ $4M | Form D |
| Apr 9, 2025 | Security to be acquired | $3.6M/ $3.6M | Form D |
| Feb 12, 2025 | Security to be acquired | $600K/ $600K | Form D |
RNA Therapeutics
Elixirgen Therapeutics' mRNA platform is at the forefront of developing innovative therapeutics designed to address rare and complex diseases. This platform enables the creation of potent treatments that can potentially modulate genetic expressions to treat conditions effectively.
Built for
Patients with rare diseases
